Basel-based biotech group Swiss Rockets has acquired U.S. life sciences company Complete Genomics. The acquisition will strengthen Swiss Rockets’ portfolio, adding sequencing capabilities to support its activities in targeted cancer therapies and developing next-generation vaccines.

总部位于巴塞尔的生物技术集团 Swiss Rockets 收购了美国生命科学公司 Complete Genomics。此次收购将加强 Swiss Rockets 的产品组合，增加测序能力以支持其在靶向癌症治疗和开发下一代疫苗方面的活动。

Founded in 2018, the

成立于2018年，

Swiss Rockets Group

瑞士火箭集团

is an innovative umbrella company with a portfolio of several niche-leading biotech companies ranging from late-stage pre-clinical to Phase III. Its portfolio with a focus on oncology includes projects in radioligand therapies, small molecules and live-attenuated virus vaccines across preclinical and clinical stages..

是一家创新的伞形公司，拥有多个处于晚期临床前至III期的细分领域领先的生物技术公司。其专注于肿瘤学的投资组合包括放射配体疗法、小分子和减毒活病毒疫苗等处于临床前和临床阶段的项目。

The company recently concluded a deal with

公司最近达成了一项协议

Complete Genomics

完整基因组学

for its full acquisition. Complete Genomics, founded in 2005, develops DNA sequencing platforms, reagents and software for research applications. The transaction has already received approval from Chinese authorities. Remaining approvals – including Chinese shareholder and U.S. regulatory approvals – are expected in the coming months..

为了全面收购。Complete Genomics公司成立于2005年，开发用于研究应用的DNA测序平台、试剂和软件。该交易已经获得中国当局的批准。剩余的批准——包括中国股东和美国监管机构的批准——预计将在未来几个月内完成。

With its long history in next-generation sequencing (NGS) and novel chemistries and technology, Complete Genomics complements and enables Swiss Rockets’ long-term vision by expanding access to precision medicine and wellness broadly while synergistically enabling the development of novel therapies and diagnostics..

凭借其在下一代测序（NGS）、新型化学技术和技术方面的悠久历史，Complete Genomics通过广泛扩大精准医疗和健康的可及性，同时协同促进新型疗法和诊断工具的开发，从而补充并推动了Swiss Rockets的长期愿景。

The transaction includes a share purchase agreement for the acquisition of 100% of Complete Genomics, as well as an expanded exclusive licence agreement and a development and supply agreement.

该交易包括一份收购Complete Genomics公司100%股权的股票购买协议，以及一份扩大范围的独家许可协议和一份开发与供应协议。

Complete Genomics, which became part of China-based MGI in 2018 following its acquisition by BGI in 2013, will continue to operate as a US-based company, with its management team retaining responsibility for day-to-day operations, product strategy, software development, and customer relationships. The company will be led by Vladimir Cmiljanovic, Founder, CEO and Chairperson of Swiss Rockets AG, as CEO with the management team announced at a later date..

2013年被华大基因收购、2018年成为中国MGI一部分的Complete Genomics将继续作为一家美国公司运营，其管理团队仍负责日常运营、产品战略、软件开发和客户关系。该公司将由瑞士火箭公司（Swiss Rockets AG）创始人、首席执行官兼董事长弗拉基米尔·茨米利亚诺维奇（Vladimir Cmiljanovic）担任首席执行官，管理团队将于日后公布。

“Swiss Rockets recognized Complete Genomics’ strong position in developing and delivering cost-effective, flexible sequencing solutions and saw an opportunity to accelerate innovation and expand market reach,” said Vladimir Cmiljanovic. “We are excited to support the team as they expand their technology portfolio, strengthen supply chain resilience, and accelerate their impact on genomics research worldwide.”.

“瑞士火箭公司认识到Complete Genomics在开发和提供高性价比、灵活的测序解决方案方面的强大优势，并看到了加速创新和扩大市场覆盖的机会，”弗拉基米尔·茨米亚诺维奇表示。“我们很高兴支持该团队扩展其技术组合，增强供应链弹性，并加速其对全球基因组学研究的影响。”

(Press release/AJ)

（新闻稿/AJ）

Photo L-R: Wang Jian, Vladimir Cmiljanovic, Radoje Drmanac

照片从左到右：王坚、弗拉基米尔·茨米利亚诺维奇、拉多耶·德拉马纳克

0

0

Comments

评论

Back to all news

返回所有新闻

Please

请

login

登录

or

或

sign up

注册

to comment.

评论。

Commenting guidelines

评论指南

Send

发送